Roles > ergosterol biosynthesis inhibitor
Page last updated: 2024-08-05 15:43:19
ergosterol biosynthesis inhibitor
Any compound that inhibits one or more steps in the pathway leading to the synthesis of ergosterol.
ChEBI ID: 75282
Members (2)
| Member | Definition | Class |
|---|
| isavuconazole | A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis. | isavuconazole |
| ravuconazole | A member of the class of triazoles that is 1-butyl-1H-1,2,4-triazole in which the butyl group is substituted at positions 2, 2, and 3 by hydroxy, 2,4-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively (the R,R stereoisomer). It exhibits antifungal activity by inhibition of 14alpha demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCIO4) | ravuconazole |
Research
Studies (480)
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (2.50) | 18.2507 |
| 2000's | 81 (16.88) | 29.6817 |
| 2010's | 225 (46.88) | 24.3611 |
| 2020's | 162 (33.75) | 2.80 |
Study Types
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|
| Trials | 44 (8.78%) | 5.53% |
| Reviews | 81 (16.17%) | 6.00% |
| Case Studies | 64 (12.77%) | 4.05% |
| Observational | 3 (0.60%) | 0.25% |
| Other | 309 (61.68%) | 84.16% |
Protein Targets (11)
Potency Measurements
Inhibition Measurements